{
  "nct_id": "NCT01782443",
  "study_title": "Ziv-Aflibercept for Advanced Progressive Carcinoid Tumors",
  "search_date": "2025-07-15T14:01:34.569531",
  "publications_found": 1,
  "publications": [
    {
      "pmid": "36395401",
      "title": "Perez K, Kulke MH, Horick NK, Regan E, Graham C, Scheutz S, Stonely D, Enzinger PC, Fuchs CS, Allen ...",
      "authors": [],
      "journal": "From Clinical Trial Data",
      "year": "N/A",
      "doi": null,
      "abstract": "Perez K, Kulke MH, Horick NK, Regan E, Graham C, Scheutz S, Stonely D, Enzinger PC, Fuchs CS, Allen JN, Enzinger AC, Clark JW, Chan JA. A Phase II Study of Ziv-Aflibercept in Patients With Advanced Extrapancreatic Neuroendocrine Tumors. Pancreas. 2022 Aug 1;51(7):763-768. doi: 10.1097/MPA.0000000000002099.",
      "url": "https://pubmed.ncbi.nlm.nih.gov/36395401/",
      "source": "study_data"
    }
  ]
}